Development of miltefosine for the leishmaniases.
The leishmaniases consist of visceral and cutaneous syndromes present in > 30 endemic regions of the world. Miltefosine (hexadecylephosphocholine) is the first oral agent that is effective and tolerated for both visceral and cutaneous disease in several endemic regions, and represents a major advance in the treatment of these diseases.
National Center For Complementary and Alternative Medicine, National Institutes of Health, 6707 Democracy Blvd, Suite 401, Bethesda MD, 20892 USA. Bermanjo@mail.nih.gov
J D
JD
Berman
D000328:Adult; D000981:Antiprotozoal Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002986:Clinical Trials as Topic; D015195:Drug Design; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007896:Leishmaniasis / Q000150:complications / Q000188:drug therapy*; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine